Effect of CYP3A5 genotype on the extent of CYP3A inhibition by verapamil.

被引：3
|
作者：
Wang, Y [1 ]
Jin, Y [1 ]
Hilligoss, JK [1 ]
Ho, H [1 ]
Hamman, MA [1 ]
Hu, Z [1 ]
Gorski, JC [1 ]
Hall, SD [1 ]
机构：
[1] Indiana Univ, Sch Med, Indianapolis, IN USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2005年 / 77卷 / 02期
关键词：
D O I：
10.1016/j.clpt.2004.11.014
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P3 / P3
页数：1
相关论文
共 50 条
  • [41] Impact of CYP3A5 genotype on tolvaptan pharmacokinetics and their relationships with endogenous markers of CYP3A activity and serum sodium level in heart failure patients
    Hoshikawa, Kohei
    Naito, Takafumi
    Akutsu, Shunta
    Saotome, Masao
    Maekawa, Yuichiro
    Kawakami, Junichi
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2020, 126 (04) : 353 - 363
  • [42] Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil
    Langaee, T. Y.
    Gong, Y.
    Yarandi, H. N.
    Katz, D. A.
    Cooper-DeHoff, R. M.
    Pepine, C. J.
    Johnson, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (03) : 386 - 391
  • [43] Elevated oral clearance of verapamil in CYP3A5 expressers.
    Jin, Y
    Wang, Y
    Hamman, MA
    Marunde, R
    Hu, Z
    Hilligoss, J
    Hall, SD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P40 - P40
  • [44] Differences in verapamil response between CYP3A5 genotypes.
    Langaee, TY
    Yarandi, HN
    Katz, DA
    Dehoff, RM
    Kehoe, JM
    Klocman, AS
    Pepine, CJ
    Johnson, JA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P12 - P12
  • [45] Effect of Simultaneous Induction and Inhibition of CYP3A by St John's Wort and Ritonavir on CYP3A Activity
    Hafner, V.
    Jaeger, M.
    Matthee, A-K
    Ding, R.
    Burhenne, J.
    Haefeli, W. E.
    Mikus, G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (02) : 191 - 196
  • [46] Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects
    Kim, Kyoung-Ah
    Park, Pil-Whan
    Lee, Ock-Je
    Choi, Sang-Hyun
    Min, Bon Hong
    Shin, Kyung-Ho
    Chun, Boe-Gwun
    Shin, Jae-Gook
    Park, Ji-Young
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (06) : 646 - 656
  • [47] Effect of CYP3A5*3 genotype on exposure and efficacy of quetiapine: A retrospective, cohort study
    Zhao, Yan
    Hao, Yupei
    Wang, Ziyi
    Liu, Shuai
    Yuan, Shizhao
    Zhou, Chunhua
    Yu, Jing
    JOURNAL OF AFFECTIVE DISORDERS, 2025, 370 : 134 - 139
  • [48] EFFECT OF CYP3A4*22, CYP3A5*3 AND CYP3A COMBINED GENOTYPES ON ENDOXIFEN SERUM CONCENTRATIONS IN BREAST CANCER PATIENTS USING TAMOXIFEN.
    Spitman, A. B. Sanchez
    Moes, D. -J. A.
    Gelderblom, H.
    Dezentje, V. O.
    Swen, J. J.
    Guchelaar, H. -J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S48 - S48
  • [49] CYP3A5 Genotype-Phenotype Analysis in the Human Kidney Reveals a Strong Site-Specific Expression of CYP3A5 in the Proximal Tubule in Carriers of the CYP3A5*1 Allele
    Bolbrinker, Juliane
    Seeberg, Stefanie
    Schostak, Martin
    Kempkensteffen, Carsten
    Baelde, Hans
    de Heer, Emile
    Kreutz, Reinhold
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (04) : 639 - 641
  • [50] GLOBAL ANALYSIS OF CYP3A4 AND CYP3A5 GENOTYPE ON IN VIVO CLEARANCE OF CYP3A4 SUBSTRATES.
    Quinney, S. K.
    Schwartz, J. B.
    Hall, S. D.
    Gorski, J. C.
    Li, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S49 - S49
12345